Progress in Hepatocellular Carcinoma Treatment

  • Kiwamu Okita
Conference proceedings

Table of contents

  1. Front Matter
    Pages II-XI
  2. Kwang-Hyub Han, Jeong Il Jeong, Sang Hoon Ahn, Dong Kee Kim, Chae Yoon Chon, Young Myoung Moon
    Pages 1-9
  3. Shuichiro Shiina, Takuma Teratani, Masatoshi Imamura, Shuntaro Obi, Shinpei Sato, Yukihiro Koike et al.
    Pages 10-16
  4. Toshihito Seki, Taiichi Nakagawa, Toru Tamai, Masato Imamura, Akira Nishimura, Noriyo Yamashiki et al.
    Pages 17-22
  5. Yukihiro Shirota, Taro Yamashita, Shuichi Terasaki, Eiki Matsushita, Takeshi Urabe, Shuichi Kaneko et al.
    Pages 35-39
  6. Masatoshi Tanaka, Eiji Ando, Sigeru Yutani, Kazuta Fukumori, Ryoko Kuromatsu, Yoshihiro Shimauchi et al.
    Pages 49-55
  7. Masaaki Oka, Minekatsu Nishida, Yoshitaka Maeda
    Pages 56-63
  8. Kenji Nakamura, Sumio Takashima, Toshio Kaminou, Youichi Kohda, Masao Hamuro, Seisho Hayashi et al.
    Pages 64-75
  9. Isao Sakaida, Koji Hironaka, Kiwamu Okita
    Pages 76-85
  10. Tomohide Tatsumi, Tetsuo Takehara, Yutaka Sasaki, Masatsugu Hori, Norio Hayashi
    Pages 86-96
  11. Back Matter
    Pages 105-107

About these proceedings


According to a recent report from the Japanese Ministry of Health and Welfare, the mortality rate for hepatocellular carcinoma (HCC) is more than 30 per 100000 pop­ ulation. In addition,epidemiologists predictan increase in this figure by the year 2015, because of the rather high incidence of chronic liver diseases caused by HCY. The same situation has been observed in other Asian countries. It seems that HCC is likely to be an endemic disease, because of the higher preva­ lence of chronic hepatitis and liver cirrhosis caused by HBV, HCV, and/or aflatoxins in Asian and African countries. We also note that an interesting paper appeared in a recent issue of the New England Journal of Medicine describing the increase in younger HCC patients in the United States as compared with past decades. At present, silent hepatitis C infection is now smoldering in 4 million mostly unsuspecting Americans. Those carriers will be candidates for chronic liver disease, which is a pre­ disposing factor for the development of HCC. In Europe there are an estimated 5 million carriers. Accordingly, it is important to do all we can to reduce the prevalence of HCC not only in African and Asian countries, but also in the United States and Europe. With this perspective,last year the Japanese Society for Hepatology, in cooperation with the Ministry of Health and Welfare, initiated a national campaign to fight HCC.


cancer carcinogenesis carcinoma hepatitis liver liver disease lymphocytes prevention screening

Editors and affiliations

  • Kiwamu Okita
    • 1
  1. 1.First Department of Internal MedicineYamaguchi University School of MedicineUbe, YamaguchiJapan

Bibliographic information